Figure 2
Figure 2. The cumulative incidence of relapse (CIR) between KIT+/MRD+ group and KIT-MRD- group when receiving chemotherapy/auto-HSCT(A) and allo-HSCT(B) as postremission treatments in t(8;21) AML patients.

The cumulative incidence of relapse (CIR) between KIT+/MRD+ group and KIT-MRD- group when receiving chemotherapy/auto-HSCT(A) and allo-HSCT(B) as postremission treatments in t(8;21) AML patients.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal